Fundraising Overview - The company raised a total of RMB 455.5322 million through its initial public offering, with a net amount of RMB 390.9331 million after deducting various issuance costs [1][2] - The funds were raised by issuing 20.200986 million shares at a price of RMB 22.55 per share [1] Fund Utilization and Balance - As of December 31, 2022, the company had a remaining balance of RMB 336.43 million in its fundraising account, with RMB 4.70846 million used for projects and RMB 1.69811 million for issuance costs [2] - By December 31, 2023, the remaining balance was RMB 236.3034 million, with RMB 9.35421 million utilized for projects [2] - As of December 31, 2024, the remaining balance was RMB 137.4138 million, with RMB 8.77753 million used for projects [2] - As of June 30, 2025, the remaining balance was RMB 114.5452 million, with RMB 2.37295 million utilized for projects [2] Fund Management - The company has established a fundraising management system to ensure the effective use of funds and protect investor rights [3] - Funds are stored in designated bank accounts, and a tripartite supervision agreement has been signed with the underwriter and banks [3] Project Completion and Remaining Payments - Several projects funded by the raised capital, including the R&D center and marketing network construction, have been completed, with remaining payments totaling RMB 30.1286 million [2][3] - The company has used part of the raised funds to replace self-raised funds for issuance costs, amounting to RMB 4.6433 million [6][11] Idle Fund Management - The company has approved the use of idle funds for cash management, with a limit of RMB 100 million [5][6] - As of June 30, 2025, RMB 42 million of idle funds were allocated for cash management [12]

证券代码：301130 证券简称：西点药业 公告编号：2025-056 吉林省西点药业科技发展股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 8 月 度的议案》。本次关于部分制度的修订事项尚需提交股东大会审议。现将有关情 况公告如下： 为进一步促进公司规范运作，建立健全内部管理机制，根据《中华人民共和 国公司法》 《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》 《深 《关联交易管理制度》 《回购股份 管理制度》 《累积投票制实施细则》 《募集资金管理制度》 《内部审计制度》 《内幕 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上 市公司章程指引》《上市公司股东会规则》等法律、法规及规范性文件的最新规 定，结合公司实际情况，现对公司《独立董事工作制度》《独立董事专门会议规 则》 《对外担保管理制度》 《对外投资管理制度》 特此公告。 吉林省西点药业科技发展股份有限公司董事会 信息知情人登记管理制度》《投资者关系管理制度》《委托理财管理 ...

Group 1 - The company is Jilin Xidian Pharmaceutical Technology Development Co., Ltd. [1] - The document includes financial data for the year 2025, specifically for the first half of the year [2] - The financial data includes details on fund occupation and related party transactions [2] Group 2 - The document outlines non-operating fund occupation and the reasons for such occupations [2] - It specifies the amounts involved in fund occupation and the interest associated with these transactions [2] - The document also mentions the relationships with controlling shareholders and affiliated companies [2]

Core Points - The company establishes rules for independent director meetings to ensure compliance and protect the rights of all shareholders, especially minority shareholders [1] - Independent directors are required to hold at least one regular meeting annually and can convene additional meetings as necessary [2][3] - The company must provide support for the convening of independent director meetings and ensure timely delivery of relevant materials to all independent directors [2][3] Group 1 - Independent director meetings are to be held when specific matters arise, including related party transactions and changes in commitments [1][2] - Meetings can be conducted in person or through other means such as video or phone, ensuring effective communication among independent directors [2][3] - Decisions made during independent director meetings require a majority vote from all independent directors present [3][4] Group 2 - Independent directors must personally attend meetings or provide written opinions if unable to attend [3][4] - Independent directors are obligated to maintain confidentiality regarding meeting discussions and decisions [4][5] - The rules will be executed upon approval by the company's board of directors and will be revised as necessary to comply with national laws and regulations [5]

吉林省西点药业科技发展股份有限公司 第一章 总则 第一条 为了促进吉林省西点药业科技发展股份有限公司（以下简称公司） 的规范运作，维护公司整体利益，保障全体股东特别是中小股东的合法权益不受 损害，根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国 证券法》（以下简称《证券法》），中国证券监督管理委员会（以下简称"中国证 监会"）《上市公司独立董事管理办法》（以下简称《管理办法》）《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称《规 范运作指引》）等法律、行政法规、规范性文件和《吉林省西点药业科技发展股 份有限公司章程》（以下简称《公司章程》）的有关规定，制定本制度。 第二章 一般规定 （一）具备注册会计师资格； （二）具有会计、审计或者财务管理专业的高级职称、副教授或以上职称、 博士学位； （三）具有经济管理方面高级职称，且在会计、审计或者财务管理等专业岗 位有五年以上全职工作经验。 第六条 独立董事出现不符合独立性条件或其他不适宜履行独立职责的情形， 由此造成本公司独立董事不符合本制度要求的人数时，公司应按规定补足独立董 事人数。 第七条 独立董事应当持 ...

吉林省西点药业科技发展股份有限公司 第一章 总 则 第一条 为规范和完善吉林省西点药业科技发展股份有限公司（以下简称公 司）募集资金存储、使用、变更、监督和责任追究的制度，明确募集资金使用的 分级审批权限、决策程序、风险控制措施及信息披露要求，保证募集资金项目的 正常进行和有效管理，提高募集资金使用效率，保护股东权益，根据《中华人民 共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《上市公司募集资金监管规则》等法律法规、规范性文件及《吉林省西点药业科 技发展股份有限公司章程》（以下简称《公司章程》）规定，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括上市公司实施股权激励 计划募集的资金。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能 ...

Core Points - The document outlines the procedures and principles for the resignation of directors at Jilin Xidian Pharmaceutical Technology Development Co., Ltd, ensuring compliance with laws and regulations [1][2][3] - The company emphasizes the importance of maintaining governance stability and protecting shareholder rights during the director resignation process [1][2] Group 1: Resignation Procedures - Directors who fail to attend board meetings twice consecutively without delegation are considered unable to fulfill their duties, leading to a recommendation for their replacement [2] - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company [2] - The company must disclose the resignation details within two trading days and complete the re-election of directors within sixty days to ensure compliance with legal requirements [2][3] Group 2: Responsibilities and Obligations of Resigning Directors - Resigning directors must complete all handover procedures within five days of their official departure, including the transfer of relevant documents and responsibilities [4] - Directors are required to continue fulfilling any public commitments made during their tenure, even after resignation [4][5] - The confidentiality obligations regarding company trade secrets remain in effect after a director's departure until such information becomes public [5] Group 3: Shareholding Management - Resigning directors are prohibited from transferring their shares within six months of leaving the company [6] - Any changes in shareholding must comply with previously made commitments regarding shareholding proportions and durations [6][6] - The company secretary is responsible for monitoring the shareholding changes of resigning directors and reporting to regulatory authorities if necessary [6]

吉林省西点药业科技发展股份有限公司 第一章 总则 第一条 为规范吉林省西点药业科技发展股份有限公司（以下简称"本公司" 或"公司"）重大信息内部报告工作，保证公司内部重大信息的快速传递、归集 和有效管理，及时、准确、全面、完整地披露信息，维护投资者的合法权益，根 据《中华人民共和国公司法》 《中华人民共和国证券法》 （以下简称"《证券法》"） 《上市公司信息披露管理办法》《深圳证券交易所创业板股票上市规则》（以下 简称"《上市规则》"）《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律法规及《吉林省西点药业科技发展股份有 限公司章程》（以下简称"《公司章程》"）的要求，结合公司实际，制定本制 度。 第二条 公司重大信息报告制度是指当出现、发生或即将发生可能对公司股 票及其衍生品种交易价格或者投资决策产生较大影响的情形或事项（以下简称重 大信息、重大事件或者重大事项）时，按照本制度规定负有报告义务的有关人员 和公司，应当在第一时间将相关信息向公司董事会和董事会秘书报告的制度。 第三条 董事会秘书负责组织实施具体的信息披露工作。证券部为公司信息 披露工作的管理部门，负责公开信息 ...

Core Points - The document outlines the regulations for the management and usage of seals at Jilin Xidian Pharmaceutical Technology Development Co., Ltd, emphasizing the importance of legality, seriousness, and security in seal usage [1][2][3] Seal Management and Usage - The company seals include the official seal, legal representative seal, contract special seal, financial special seal, board seal, and departmental seals [1] - The official and legal representative seals are managed by the company office, while the contract special seal is managed by the sales and procurement departments, and the financial special seal is managed by the finance department [1] - Seals must be stored securely, and the responsible personnel must ensure they are clean and well-maintained [1][2] - Usage of seals requires prior approval from department heads and must be authorized by a vice manager or higher [1][2][3] Seal Usage Procedures - A standardized "Seal Usage Approval Form" and "Seal Usage Registration Form" are to be used for tracking seal usage [2] - The seal usage process mandates prior approval; unauthorized usage is prohibited [2][3] - The seal custodian must personally use the seal and cannot delegate this responsibility [3] Responsibilities and Accountability - The company will conduct regular checks on seal usage and management, and any loss or theft must be reported immediately [4] - Violations of the seal management procedures can lead to disciplinary actions, including economic penalties or criminal liability [4] - The seal custodian's responsibilities are included in the employee exit process, ensuring proper handover of seals upon departure [4]

Core Points - The company establishes a system for entrusted financial management to ensure the safety of funds and assets, effectively control investment risks, and protect the rights and interests of shareholders [1][2] - The entrusted financial management refers to the investment and management of the company's idle funds by professional financial institutions [1] - The system applies to the company, wholly-owned subsidiaries, and controlling subsidiaries [1] Summary by Sections General Principles - The company must use idle self-owned funds for entrusted financial management without affecting normal operations and investment needs [1] - Qualified financial institutions with good credit and financial status must be selected as trustees, and a written contract must be signed [2] - Financial products must be operated under the company's name, not under others' accounts [2] Approval and Management - Entrusted financial management reaching certain thresholds must be submitted for shareholder meeting approval, including when it exceeds 50% of total assets or 50% of net assets over 50 million [5] - The board of directors must approve entrusted financial management exceeding 10% of total assets or 10% of net assets over 1 million [6] - The company cannot delegate approval authority to individual directors or management [7] Management Responsibilities - The finance department is responsible for planning, managing, and accounting for entrusted financial management [4] - The finance department must conduct feasibility analysis and risk assessment before investment [4] - The finance department must track the progress and safety of entrusted funds and report any issues promptly [5] Supervision and Risk Control - The internal audit department supervises the financial management business, reviewing approval, operation, and fund usage [6] - The audit committee has the right to inspect entrusted financial products and may hire external professionals for assistance [6] - Any violations of laws or regulations will lead to accountability for responsible personnel [6][7]